Search REGN
REGENERON PHARMACEUTICALS, INC.
Nasdaq · CIK 872589
Last close735.2
Daily change+0.39 (0.05%)
10 Years gain+84.09%
Dividends TTM3.7 (+40.15%)
Dividend yield0.50%
Fundamental Analysis
REGN · STANDARD
SIC 2834 · Pharmaceutical Preparations · Fiscal year end 1231
Fundamental
53.0Momentum
48.3Acceleration
45.9Confidence
91.0Annual Revenue18
Quarterly Revenue73
Annual CFO18
Balance SheetAvailable
RankingEligible
Score Breakdown
Growth10.6 / 25
Quality9.3 / 25
Capital Efficiency5.1 / 20
Balance Sheet15.0 / 15
Shareholder Economics9.3 / 10
Forward Indicators3.7 / 5
Signals
Net debt reductionNet debt declined versus the comparison period.
Share count reductionDiluted share count declined 4.6763%.
Warnings
Gross margin compression · MEDIUMGross margin compressed by 2.098 percentage points.
Key Metrics
Revenue Growth TTM14.02%OK
Revenue CAGR 3Y5.62%OK
Gross Margin82.97%OK
Operating Margin26.38%OK
FCF Marginn/aMISSING
FCF Growthn/aINSUFFICIENT_HISTORY
ROIC13.49%OK
Incremental Operating Margin 3Y-385.81%OK
Net Debt / CFOn/aNOT_MEANINGFUL
Diluted Share Growth 1Y-4.68%OK
SBC / Revenuen/aMISSING
SBC / FCFn/aNOT_MEANINGFUL
Financial History
| Period | Revenue | Gross Profit | Operating Income | CFO | FCF | Gross Margin | Op Margin | FCF Margin | ROIC | Shares |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025 FY Dec 31, 2025 | $14.34B | $12.13B | $3.58B | $4.98B | $4.08B | 84.56% | 24.95% | 28.45% | 13.12% | 108.6M |
| 2025 FY Dec 31, 2024 | $14.20B | $12.08B | $3.99B | $4.42B | $3.66B | 85.04% | 28.1% | 25.8% | 18.68% | 115.1M |
| 2025 FY Dec 31, 2023 | $13.12B | $11.12B | $4.05B | $4.59B | $3.88B | 84.75% | 30.85% | 29.54% | 22.4% | 113.7M |
| 2024 FY Dec 31, 2022 | $12.17B | $10.45B | $4.74B | $5.01B | $4.42B | 85.82% | 38.93% | 36.35% | 26.48% | 113.5M |
| 2023 FY Dec 31, 2021 | $16.07B | $13.63B | $8.95B | $7.08B | $6.53B | 84.82% | 55.67% | 40.63% | 63.32% | 112.2M |
Formula Trace
| Metric | Value | Formula | Status | Source |
|---|---|---|---|---|
| Revenue TTM | $15.33B | sum latest 4 fiscal quarters Revenue | OK | 0000872589-26-000025, 0000872589-25-000028 |
| Revenue Growth TTM | 14.02% | Revenue_TTM / Revenue_TTM_1Y_ago - 1 | OK | 0000872589-26-000025, 0000872589-25-000028 |
| Revenue CAGR 3Y | 5.62% | (Revenue_current / Revenue_3Y_ago)^(1/3) - 1 | OK | 0000872589-26-000008 |
| Revenue CAGR 5Y | 11.04% | (Revenue_current / Revenue_5Y_ago)^(1/5) - 1 | OK | 0000872589-26-000008 |
| Gross Profit CAGR 3Y | 5.1% | (GrossProfit_current / GrossProfit_3Y_ago)^(1/3) - 1 | OK | 0000872589-26-000008 |
| Operating Income Growth | 12.54% | OperatingIncome_current / OperatingIncome_prior_year - 1 | OK | 0000872589-26-000025, 0000872589-25-000028 |
| FCF Growth | n/a | FCF_current / FCF_prior_year - 1 | INSUFFICIENT_HISTORY | derived |
| Revenue Growth Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Profit Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Operating Income Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| FCF Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Margin | 82.97% | Gross Profit / Revenue | OK | 0000872589-26-000025, 0000872589-25-000028 |
| Operating Margin | 26.38% | Operating Income / Revenue | OK | 0000872589-26-000025, 0000872589-25-000028 |
| ROIC | 13.49% | NOPAT / Average Invested Capital | OK | 0000872589-26-000025, 0000872589-25-000028 |
| Net Debt / CFO | n/a | Net Debt / CFO | NOT_MEANINGFUL | 0000872589-26-000025 |
| Current Ratio | 3.34x | Current Assets / Current Liabilities | OK | derived |
| Cash / Debt | 4.02x | (Cash + Short-term Investments) / Total Debt | OK | 0000872589-26-000025 |
| Revenue per Diluted Share | $144.58 | Revenue / Diluted Shares | OK | 0000872589-26-000025, 0000872589-25-000028 |